Ann: Mesoblast Update on COVID-19 ARDS Trial, page-917

Could somebody please gracefully clarify for me if Remestemcel-L is still a viable treatment for a-GVHD?

The panic selling tells me I've missed something in the announcement, yet I cannot see any indication that Remestemcal-L has lost its utility for treating a-GVHD.

Before the blaster dropped the bright idea on using Remestemcel-L for ARDS, RYONCIL was looking really good with the FDA, application for the BLA was fast tracked April 1st. That was only with regards to a-GVHD, nothing to do ARDS.
So can anyone point me to the announcements where:
1: The Remestemcel-L (fast track approved) BLA was hijacked by the ARDS BLA (or clarify when the two became one)
2: The Remestemcel-L treatment was deemed ineffective to treat a-GVHD

FWIW
As a LT holder, MSB's pursuit of a treatment for ARDS always felt a bit disingenuous and "bandwagony" to me. I believed in the treatments and processes undertaken by MSB before SI felt it necessary to cash in on the COVID hype. I still do, yet I have to sit here and wonder why RYONCIL was used for ARDS when so much had been accomplished and so much was on the line with a-GVHD.